Anti-idiotype breast cancer vaccine 11D10

Drug Profile

Anti-idiotype breast cancer vaccine 11D10

Alternative Names: 11D10; Anti-idiotype monoclonal antibody 11D10; Monoclonal antibody 11D10

Latest Information Update: 01 May 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 15 Apr 1999 A clinical study has been added to the adverse events section and the Cancer immunogenicity section (739418
  • 08 Sep 1998 Profile reviewed
  • 27 Aug 1996 Preclinical development for Breast cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top